Pulmonx to Participate at Upcoming Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences. Management will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 12:20 PM PT / 3:20 PM ET, available via webcast on their website. Additionally, they will attend investor meetings at the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum on November 18, 2021. Pulmonx specializes in minimally invasive treatments for severe lung diseases, including emphysema and COPD, with over 100,000 Zephyr Valves used globally.
Details
News Market Reaction – LUNG
The recorded move for LUNG in the trading session of this news was +7.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming virtual investor conferences.
Pulmonx management is scheduled to present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 12:20pm PT / 3:20pm ET. Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
Pulmonx management will also be participating in investor meetings at the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.